Cell and gene therapies are taking off in a big way in Europe. As the buzz grows, the Swedish firm Ilya Pharma has raised €8.5M to lay down the foundations of bacterial gene therapies for enterocolitis and diabetic ulcers.
Therapeutic concepts, work and science being recognised for significant contributions in the advanced therapy pipeline in the MedicineMakers PowerList 2021.
The team also published an expert opinion on the mechanism of actions explored and progress of pipeline in 2019 in Öhnstedt et al., Expert Opinion on Drug Discovery 2019;14(5):485-497.
The scientific findings of macrophages regulating blood flow in injured tissue and how CXCL12 is therapeutically facilitating this mechanism of action accelerating healing is highlighted by Nature Cardiology Reviews. Original article: Vågesjö, E. et al. Perivascular macrophages regulate blood flow following tissue damage. Circ. Res. https://doi.org/10.1161/CIRCRESAHA.120.318380 (2021)
Our CEO Evelina Vågesjö is listed for Advanced therapies by the TheMedicineMaker together with the former Head och Cell- and Genetherapies at Novartis bringing the first CAR T cell therapy to market and the recent Nobel Laureates and users of the CRISPER technology. The ILP-drug candidates and the lead candidate ILP100 developed in Topical and Oral formulations is indeed advanced therapy, it is a next generation immunotherapy and are developed to treat wounds in skin and mucosa.